{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:35:31Z","timestamp":1786977331628,"version":"build-2736575974"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,5]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Folate receptor \u03b1 (FR\u03b1) is a glycosylphosphatidylinositol\u2010anchored protein that facilitates folate transport and has emerged as a promising therapeutic target for ovarian cancer, particularly due to its association with tumor progression. This Phase I study investigated the safety, tolerability, pharmacokinetics, and preliminary efficacy of mirvetuximab soravtansine (MIRV), an antibody\u2010drug conjugate targeting folate receptor \u03b1 (FR\u03b1), in Chinese patients with FR\u03b1\u2010overexpressed platinum\u2010resistant ovarian cancer.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This study enrolled 19 Chinese patients with previously treated FR\u03b1\u2010overexpressed ovarian cancer in the dose escalation phase (5\u2009mg\/kg,\n n<\/jats:italic>\n \u2009=\u20094; 6\u2009mg\/kg,\n n<\/jats:italic>\n \u2009=\u20093) and dose expansion phase (\n n<\/jats:italic>\n \u2009=\u200912). MIRV was administered in escalating doses from 5 to 6\u2009mg\/kg (adjusted ideal body weight), following a 3\u2009+\u20093 dose\u2010escalation design. The trial is registered with\n chinadrugtrials.org.cn<\/jats:ext-link>\n (CTR20211876).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Median treatment exposure were 9.9\u2009weeks for the 5\u2009mg\/kg cohort (\n n<\/jats:italic>\n \u2009=\u20094) and 13.1\u2009weeks for the 6\u2009mg\/kg cohort (\n n<\/jats:italic>\n \u2009=\u200915). The most common grade \u2265\u20093 adverse events were decreased platelet count (21.1%), decreased lymphocyte count (15.8%), and anemia (15.8%). The plasma concentration\u2010time and pharmacokinetic profiles of MIRV and the total antibody were generally comparable after the first and third doses. Pharmacokinetic analysis revealed a median time to maximum concentration (\n T<\/jats:italic>\n max<\/jats:sub>\n ) of 3.33\u2009h, mean terminal half\u2010life (\n T<\/jats:italic>\n 1\/2<\/jats:sub>\n ) of 118\u2009h, and geometric mean maximum concentration (\n C<\/jats:italic>\n max<\/jats:sub>\n ) of 137.07\u2009\u03bcg\/mL. MIRV exposures were comparable to those reported in Caucasian patients. No anti\u2010drug antibodies were detected. Among 15 efficacy\u2010evaluable patients with high\u2010grade serous ovarian cancer, the objective response rate was 26.7%, with partial responses in four patients and stable disease in seven patients.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n MIRV showed anticipated pharmacokinetics, safety, tolerability, and efficacy profiles in Chinese patients with FR\u03b1\u2010positive platinum\u2010resistant ovarian cancers, supporting its potential as a targeted therapeutic agent for this patient population.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n The trial is registered with\n chinadrugtrials.org.cn<\/jats:ext-link>\n (CTR20211876)\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/cam4.71704","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:10:42Z","timestamp":1779358242000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor \u03b1\u2010Positive Advanced Ovarian Cancer"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2175-9449","authenticated-orcid":false,"given":"Yongsheng","family":"Li","sequence":"first","affiliation":[{"name":"Chongqing University Cancer Hospital Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2829-6897","authenticated-orcid":false,"given":"Li","family":"Yuan","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Lou","sequence":"additional","affiliation":[{"name":"Harbin Medical University Cancer Hospital Harbin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Cai","sequence":"additional","affiliation":[{"name":"Zhongnan Hospital of Wuhan University Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhi","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Bengbu Medical College Bengbu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghu","family":"Li","sequence":"additional","affiliation":[{"name":"Guizhou Provincial Cancer Hospital Guiyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Henan Cancer Hospital Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingtao","family":"Long","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Gong","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaonan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Xu","sequence":"additional","affiliation":[{"name":"Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092230"},{"key":"e_1_2_12_3_1","volume-title":"Cancer Stat Facts: Ovarian Cancer","author":"Institute, NC","year":"2023"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2021.102074"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0047"},{"key":"e_1_2_12_7_1","volume-title":"Chinese Society of Clinical Oncology (CSCO) Ovarian Cancer Diagnosis and Treatment Guidelines 2020 (Chinese Edition)","author":"Clinical Oncology Guidelines Working Committee","year":"2020"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1128-0280"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.015"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389201020666181226123054"},{"issue":"2","key":"e_1_2_12_11_1","article-title":"Poly(ADP\u2010Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer","volume":"2","author":"Tattersall A.","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021046"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-014-9539-8"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30736"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-023-04575-y"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.9538"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0646"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.01.037"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.017"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2236793"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-1095"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005401"},{"key":"e_1_2_12_24_1","unstructured":"Elahere Highlights of Prescribing Information accessed March 2023 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761310s000lbl.pdf."},{"key":"e_1_2_12_25_1","unstructured":"Clinical Practice Guidelines in Oncology \u201cOvarian Cancer\/Fallopian Tube Cancer\/Peritoneal Cancer Version 1.2024 \u201dhttps:\/\/www.nccn.org\/guidelines\/guidelines\u2010detail?category=1&id=1453."},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-IGCS.385"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71704","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71704","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:12:25Z","timestamp":1781583145000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/cam4.71704"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71704","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71704"}}